HOLLISTON, Mass., July 18, 2017 -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will announce results for its second quarter 2017 after market trading hours on Thursday, July 27, 2017. A conference call to discuss the company's second quarter 2017 financial results and its operations is scheduled for that same date at 4:30 PM ET. On that call, management may respond to questions from the audience and provide information on any of a number of topics related to the business, including operations, plans and outlook.
Participating in the call will be Jeffrey A. Duchemin, President and Chief Executive Officer; and Robert Gagnon, Chief Financial Officer of Harvard Bioscience. Investors can access the live conference call by dialing the following phone numbers: toll-free 1-800-708-4539, or international: 1-847-619-6396, and referencing the conference ID# 45318167.
The conference will be simultaneously webcast and can be accessed through the Harvard Bioscience website. To listen to the webcast, log on to the webcast at:
http://investor.harvardbioscience.com/
and click on the Earnings Call icon. Financial information presented on the call, including the earnings release, will also be available on the investor relations section of the website.
If you are unable to listen to the live conference call, the webcast will be available on the Company's website through August 3, 2017.
To add this meeting to your calendar visit: http://investor.harvardbioscience.com/ and click “remind me”.
About Harvard Bioscience
Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of solutions to advance life science. Our products are sold to thousands of researchers in over 100 countries through our global sales organization, websites, catalogs, and through distributors including Thermo Fisher Scientific Inc., VWR, and other specialized distributors. We have sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, Spain, France, Canada and China. For more information, please visit our website at www.harvardbioscience.com.
CONTACTS: Corey Manchester Director, Finance and Investor Relations Tel: 508 893 8999


Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
First Western Ship Transits Strait of Hormuz Since Iran War Began
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 



